| Company Name: | Adams Respiratory Therapeutics, Inc. | | Ticker Symbol: | ARXT | | | WWW Address: | www.adamsrt.com |
| CEO: | Michael J. Valentino | | No. of Employees: | 463 |
| Common Issue Type: | CS | | Business Description: | A pharmaceutical company which focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | | | | 60.00 | 59.95 | |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 0.0 | 36.0 | 1.34 | 0.82 | 0.00 | 50.8 | 0.0 | 60.15 - 26.38 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 59.96 | $ | | PE Ratio - LTM | 50.8 | |
| Market Capitalisation | 0.0 | mil |
| Latest Shares Outstanding | 36.0 | mil |
| Earnings pS (EPS) | 0.82 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 716,205 | $ |
| Effective Tax Rate | 35.8 | % |
| Float | 32.4 | mil |
| Float as % of Shares Outstanding | 90.1 | % |
| Foreign Sales | | mil |
| Domestic Sales | 332 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 47.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 6.80 | % |
| Gross Profit Margin | 74.3 | % |
| EBITDA Margin | 19.7 | % |
| Pre-Tax Profit Margin | 19.4 | % |
| Assets Turnover | 1.1 | % |
| Return on Assets (ROA) | 12.1 | % |
| Return on Equity (ROE) | 14.2 | % |
| Return on Capital Invested (ROCI) | 14.2 | % |
| Current Ratio | 4.3 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.38 | $ |
| Cash pS | 0.91 | $ |
| Book-Value pS | 8.54 | $ |
| Tangible Book-Value pS | 5.05 | $ |
| Cash Flow pS | 1.34 | $ |
| Free Cash Flow pS | 0.14 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 7.02 | |
| Price/Tangible Book Ratio | 11.87 | |
| Price/Cash Flow | 44.7 | |
| Price/Free Cash Flow | 428.3 | |
| P/E as % of Industry Group | 56.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.1 | 98 | 7,242 | 21,719 |
| 4 Weeks | 60.15 | 59.30 | 59.53 | 0.7 | 105 | 10,711 | 182,092 |
| 13 Weeks | 60.15 | 41.02 | 43.75 | 37.1 | 153 | 11,308 | 667,148 |
| 26 Weeks | 60.15 | 34.50 | 38.68 | 55.0 | 164 | 8,758 | 1,077,195 |
| 52 Weeks | 60.15 | 26.38 | 45.07 | 33.0 | 142 | 8,671 | 2,159,073 |
| YTD | 60.15 | 59.07 | - | 0.4 | 109 | 11,488 | 229,756 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 59.97 | 59.85 | 54.48 | 44.77 | 43.90 | 1.34 | 1.34 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 99.02 | 91.3 | 60.28 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 322.08 |
| R&D | 39.79 | NA | 82.68 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 22.0 | 22.0 | 38.7 |
| Earnings % | 80.7 | 80.7 | -34.1 |
| EPS % | 79.5 | 79.5 | -35.9 |
| EPS $ | 0.35 | 0.35 | -0.46 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 39.23 |
| Current Ratio | 3.9 |
| Quick Ratio (Acid Test) | 2.3 |
| Liquidity Ratio (Cash) | 1.88 |
| Receivables Turnover | 15.5 |
| Average Collection Period | 23 |
| Working Capital/Equity | 45.4 |
| Working Capital pS | 3.50 |
| Cash-Flow pS | 0.95 |
| Free Cash-Flow pS | -0.25 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 32.12 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 13.5 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 32.75 |
| Tobin's Q Ratio | 6.77 |
| Current P/E Ratio - LTM | 50.80 |
| Enterprise Value (EV)/EBITDA | 42.75 |
| Enterprise Value (EV)/Free Cash Flow | -266.25 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 11.87 |
| Price/Book Ratio - LTM | 7.02 |
| Price/Cash Flow Ratio | 44.7 |
| Price/Free Cash Flow Ratio - LTM | 428.3 |
| Price/Sales Ratio | 6.14 |
| P/E Ratio (1 month ago) - LTM | 50.6 |
| P/E Ratio (26 weeks ago) - LTM | 37.9 |
| P/E Ratio (52 weeks ago) - LTM | 33.4 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 56.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 54.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.19 |
| Tangible Book Value pS - LTM | 5.05 |
| Book Value pS - LTM | 8.54 |
| Capital Invested pS | 7.65 |
| Cash pS - LTM | 0.91 |
| Cash Flow pS - LTM | 1.34 |
| Free Cash Flow pS - LTM | 0.14 |
| Earnings pS (EPS) | 0.82 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -2.73 |
| Free Cash Flow Margin 5YEAR AVG | -21.69 |
| Net Profit Margin | 9.2 |
| Net Profit Margin - 5YEAR AVRG. | 14.5 |
| Equity Productivity | 1.20 |
| Return on Equity (ROE) | 11.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 113.8 |
| Capital Invested Productivity | 1.20 |
| Return on Capital Invested (ROCI) | 11.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 100.4 |
| Assets Productivity | 1.20 |
| Return on Assets (ROA) | 9.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | 16.1 |
| Gross Profit Margin | 74.3 |
| Gross Profit Margin - 5YEAR AVRG. | 77.0 |
| EBITDA Margin - LTM | 19.7 |
| EBIT Margin - LTM | 19.4 |
| Pre-Tax Profit Margin | 14.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 20.5 |
| Effective Tax Rate | 35.8 |
| Effective Tax Rate - 5YEAR AVRG. | 6.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 144 |
| Revenue per Employee | 716,205 |
| Net Income per Employee | 65,937 |
| Average Collection Period | 21 |
| Receivables Turnover | 15.5 |
| Day's Inventory Turnover Ratio | 123 |
| Inventory Turnover | 2.9 |
| Inventory/Sales | 15.9 |
| Accounts Payble/Sales | 7.24 |
| Assets/Revenue | 0.83 |
| Net Working Capital Turnover | 2.65 |
| Fixed Assets Turnover | 2.19 |
| Total Assets Turnover | 1.2 |
| Revenue per $ Cash | 7.08 |
| Revenue per $ Plant | 16.78 |
| Revenue per $ Common Equity | 1.20 |
| Revenue per $ Capital Invested | 1.20 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 49.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 48.3 |
| Research & Devlopment (R&D) as % of Revenue | 7.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.2 |
|
|  
|
| |
 |  |
